<DOC>
	<DOC>NCT01850147</DOC>
	<brief_summary>The purpose of this study is to determine whether sequential application of low-dose short-term sunitinib and chemotherapy is effective in the treatment of non-small cell lung cancer after failure of conventional therapy. Safety of this regimen will also be evaluated.</brief_summary>
	<brief_title>Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologic or cytologic diagnosis of stage IIIB/IV NSCLC ECOG PS: 0,1 Unidimensional or bidimensional measurable disease Receive prior treatment including firstline platinumbased chemotherapy, standard secondline chemotherapy and 1 EGF/EGFR inhibitor Evidence of disease progression Life expectancy &gt;12 weeks Neutrophils &gt; 1.5 109/l, Platelets &gt; 100 109/l, Hemoglobin &gt; 9g/dl, Total bilirubin &lt; 1.5 UNL, AST (SGOT) and ALT (SGPT) &lt; 2.5 UNL, Alkaline phosphatases &lt; 5 UNL, Creatinine &lt; 1 UNL Preexisting hemoptysis of a severity &gt; grade 3 by NCI CTCAE criteria within 4 weeks prior to study entry Uncontrolled hypertension CHF, angina or arrhythmias LVEF &lt; 1 UNL Existing a second malignancy within 5 years Infected with HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>sunitinib</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>